<DOC>
	<DOCNO>NCT00642395</DOCNO>
	<brief_summary>Intensification autologous stem cell ( ASCT ) currently effective treatment subject 65 essential goal achieve complete response ( CR ) good partial response ( VGPR= great 90 % reduction monoclonal component ) . However , 50 % patient achieve CR/VGPR even tandem ASCT early course disease . Optimization condition regimen could improve CR/VGPR rate . The combinaison Velcade HD Melphalan never evaluate . However , conventional dos , Velcade potentiate antimyeloma effect Melphalan without induce common toxicity . This study conduct patient age 65 de novo multiple myeloma first relapse , Salmon Durie stage III , II , I one symptomatic bone lesion ( radiological ) contraindication intensification . The primary objective increase CR/VGPR rate 3 month autologous peripheral blood stem cell transplantation condition Velcade-Melphalan 40 % 70 % . With alpha=5 % bêta=10 % , 61 patient include . Secondary objective assess toxicity Velcade-Melphalan conditioning regimen , progression-free survival overall survival intensification . Response rate evaluate accord response criterion define . Analysis perform intention-to-treat basis . After conventional induction therapy PBSC collection , patient offer new condition regimen . free refuse regimen , case receive standard intensification therapy Melphalan 200 mg/m² follow autologous stem cell transplantation . Evaluation occur 3 month post intensification .</brief_summary>
	<brief_title>Velcade®-Melphalan Association Autologous Stem-Cell Transplantation ( ASCT )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>At time diagnosis De novo multiple myeloma patient 65 first relapse , screen chromosome 13 deletion beta2microglobulin assay perform . Salmon Durie Stage : III , II , I symptomatic bone lesion ( radiological ) Patient 's write informed consent No clinical sign heart failure coronary insufficiency LVEF &gt; 50 % No hepatic insufficiency : bilirubin &lt; 35μmol/l SGOT , SGPT , alkaline phosphatase le 2.5 N No respiratory insufficiency : normal pulmonary function test DLCO &gt; 50 % No preexisting renal impairment relate disease No history malignant disease exception basal cell carcinoma stage I cervical cancer Negative HIV serology Effective contraception justify At time transplantation Good performance status ( WHO score≤2 ) Creatinine≤170μmol/l ineligibility criterion intensification Stem cell harvest ≥ 5x10E6 CD34/kg 2 ASCT Absence progressive disease transplantation Known refusal subject participate study Female subject pregnant breastfeeding History allergy study medication , analogue , excipients various formulation Main liver insufficiency ≥ Grade 3 peripheral neuropathy clinical examination within 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Autologous Stem Cells Transplantation</keyword>
	<keyword>High Dose Melphalan</keyword>
	<keyword>Bortezomib</keyword>
</DOC>